Abstract: Objective To explore the efficacy and safety of traditional Chinese medicine （TCM） in combination with somatostatin analogues （SSA） therapy for advanced gastroenteropancreatic neuroendocrine tumors （GEP-NET）.
MethodsFrom September 2011 to August 2015， 39 patients with advanced GEP-NET who were treated in the Department of Integrative Oncology， China-Japan Friendship Hospital were enrolled in this study. Among 39 GEP-NET， 19 were localized in pancreas， 8 cases in rectum， 8 cases in small intestine， 1 case in stomach and 3 cases of primary unknown. All the patients received TCM plus SSA therapy. SSA was given as octreotide LAR （20mg， im， every 34 weeks） or Lanreotide （40 mg， im， every 10-14 days）. At the same time， patients were treated with Chinese herb decoction according to syndrome differentiation. Efficacy was evaluated using RECIST 1.1 criteria every 3 months. Adverse events were evaluated according to NCI-CTC 3.0. The time to progression （TTP） was observed. Serum chromogranin A （CgA） was also monitored according to the schedule. Results A total of 39 cases were evaluated for efficacy including 20 cases of disease progression and 19 cases of stable disease with the objective response rate of 0 and disease control rate of 48.7％. The median TTP was 22.9 months. The main adverse events were cholelithiasis and 1 to 2 grade diarrhea. Conclusion TCM in combination with SSA treatment may significantly prolong the TTP for advanced GEP-NET with mild adverse effects， be worthy of further clinical application widely.